Abstract

CASTRO, Christian David et al. Recurrent pleomorphic anaplastic xanthoastrocytoma and response to combination of carmustine and bevacizumab, a case report. Acta Neurol Colomb. [online]. 2018, vol.34, n.4, pp.239-244. ISSN 0120-8748.  https://doi.org/10.22379/24224022220.

The case of a young woman of 19-years-old is presented; whom the diagnosis was made of a left parietal-occipital xanthoastrocytoma pleomorphic anaplastic; this neoplasia is rare and usually affects the pediatric and young adult population. This generally debuts with seizures and their pathognomonic histologic characteristics are the pleomorphic cells with cytoplasmatic lipid vacuolation and the reactivity of glial fibrillary acidic protein (GFAP) and S100. The study of new markers that may provide other therapeutic opportunities has allowed finding mutations in the BRAF oncogene. This tumor has a more aggressive anaplastic variant that is treated with surgery and chemoradation. In our case after several progressions to other interventions, we used bevacizumab and carmustine as second-line treatment obtaining complete response.

Keywords : glioma; antineoplastic agents; radiotherapy; bevacizumab; carmustine (MeSH).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )